Huons Group Successfully Hosts Launch Symposium for Botulinum Toxin 'Hutox' in China
전체 맥락을 이해하기 위해서는 본문 보기를 권장합니다.
Huons Group is accelerating its entry into the Chinese market with its botulinum toxin product, 'Hutox'.
An official from Huons Group stated, "This Hutox Launch Symposium was a meaningful opportunity to introduce the global applications and academic value of Hutox to local Chinese medical professionals and industry experts. Moving forward, we will continue to drive diverse academic and marketing initiatives to strengthen the brand competitiveness of Hutox in the global market."
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
[NA Eun-kyung, Edaily Reporter] On the 16th, the 'Hutox Launch Symposium' was held at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China. Chief Director of Cellinique Clinic, Dr. Chris Gunwoo Kim, delivers his lecture during the event.
Huons Group is accelerating its entry into the Chinese market with its botulinum toxin product, 'Hutox'.

Huons Group affiliates Humedix and Huons BioPharma announced on the 20th the "Hutox Launch Symposium" was successfully held on the 16th at the JW Marriott Hotel in Hangzhou, Zhejiang Province, China.
The symposium was hosted by Huons BioPharma’s local Chinese partner, IMeik Technology (hereafter IMeik). The event featured the official launch announcement of the botulinum toxin product 'Hutox' in China alongside an academic exchange program.
Through this symposium, Humedix and Huons BioPharma aimed to expand broaden touchpoints with local Chinese medical professionals and industry stakeholders, while boosting the global brand awareness of Hutox.
During the event, Dr. Chris Gunwoo Kim, Chief Director of Cellinique Clinic, participated as a guest speaker to deliver a lecture on Hutox. Dr. Kim shared global trends in botulinum toxin utilization, practical clinical applications, and operational know-how for administering the product.
Hutox is an aesthetic and therapeutic pharmaceutical product with botulinum toxin as its active ingredient. It is primarily used for the improvement of glabellar lines and crow's feet.
In 2022, IMeik secured exclusive import and distribution rights for Huons BioPharma's botulinum toxin products in the Greater China region (including Macau and Hong Kong). Following this, IMeik obtained marketing authorization for Hutox from China's National Medical Products Administration (NMPA) last January.
For this launch event, Humedix leveraged its extensive network of Korean medical professionals to support the invitation of the speaker and streamline academic communications.
An official from Huons Group stated, “This Hutox Launch Symposium was a meaningful opportunity to introduce the global applications and academic value of Hutox to local Chinese medical professionals and industry experts. Moving forward, we will continue to drive diverse academic and marketing initiatives to strengthen the brand competitiveness of Hutox in the global market."
나은경 (eeee@edaily.co.kr)
Copyright © 이데일리. 무단전재 및 재배포 금지.
- '젠슨 황이 입던' 검은 가죽재킷, 14억원에 낙찰…예상가 16배
- 전국 곳곳 거센 장맛비…낮 최고 33도 무더위 계속[오늘날씨]
- '북중미WC 우승팀' 스페인, 2천만원 육박 다이아 반지도 받는다
- 트럼프, 대러 제재안에 이란 포함 촉구…관세 압박 확대
- 나경원 "AI 이름 팔아 국민 돈 갈취…김용범, 레버리지 사태 수습·사퇴하라"
- 이란 혁명수비대 "호르무즈 배 2척 멈춰…美에 속아 진입하면 사고"
- 연휴 사흘간 폭우…전국서 500명 긴급대피(종합)
- 美 "아카바 공항·항구 접근 자제"…요르단 "소개령 없어"
- 김민석 "전당대회 본질은 반명 분열주의·신천지와의 대회전"
- 구자철 "한국 축구 망했다…5·10년 후 참담한 현실 마주할 것"